Control Bionics Limited (CBL) Fair Value & Analysis
Healthcare · AU · Market cap A$32.5M
Fair value as of: Jun 24, 2026
From 4 valuation models · updated 5 days ago
Share price +46.4% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0297 – A$0.0987 · fair‑value band A$0.0500 – A$0.0800 · the A$0.0870 price screens above the A$0.0600 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Control Bionics Limited (CBL) currently trades at A$0.0870, while our model-based Fair Value estimate is A$0.0600 — implying the stock looks roughly 31.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$6.1M. Revenue declined 2.6% year over year. It earns a return on equity of -91.6%. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. The company also provides the NeuroStrip, a wearable, miniaturized electromyography device; NeuroNode, a wireless, wearable sensor that allows users to access technology through bioelectric signals and spatial movements; and Cosmos Connect, a small portable control device that turns a single NeuroNode sensor into multiple outputs. In addition, it offers mounting systems under the Rehadapt brand, including wheelchair mounts, floor stands, and table stands; switch systems comprising proximity, press, and finger switches; a…
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Control Bionics Limited reported revenue of A$6.1M in FY2024 versus A$4.1M in FY2020, a compound +10.7%/yr. Reported net income was −A$6.1M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.21 | R$43.74 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Control Bionics Limited (CBL) undervalued?
What is the fair value of CBL?
What is the quality score of CBL?
What is the revenue of Control Bionics Limited (CBL)?
What is the net profit margin of CBL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.